Lupus Foundation of America

Aurinia Pharmaceuticals initiates phase IIb trial of Voclosporin for lupus nephritis

Friday, June 27, 2014

Aurinia Pharmaceuticals has enrolled the first patient in its planned phase IIb clinical trial to evaluate the efficacy of voclosporin as a treatment for lupus nephritis (LN). LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition. The Lupus Foundation of America believes there are as many as 1.5 million people in the U.S. with systemic lupus erythematosus (SLE), approximately 40% to 70% of whom will develop LN.

[Read More]

Lupus Foundation of America launches new monitoring tool

Thursday, March 20, 2014

The Lupus Foundation of America is funding and leading the development of a first-of-its-kind tool to monitor lupus disease activity called the Rapid Evaluation of Activity in Lupus (LFA-REAL) System. LFA-REAL will address major challenges in lupus treatment and disease management, and has the potential to greatly improve medical care and quality of life for people living with the autoimmune disease.

[Read More]